Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
Figure 1
The graph shows the viral kinetics of the 13 subjects during treatment with CIFN and weight-based ribavirin. None of the subjects with an initial drop in HCV RNA, including subject 11 who had transient undetectable HCV RNA at week 20, failed to achieved a sustained loss of HCV RNA.
